Protagonist Therapeutics signs $300M upfront collaboration with Takeda for rusfertide

Protagonist Therapeutics, Inc

Takeda pays $300M upfront within 30 days of HSR clearance; 50/50 profit-loss share in U.S.
Tiered royalties of 10-17% in ex-US territory; up to 29% if opt-out exercised.
Milestones up to $330M (no opt-out) or up to $975M (with opt-out); plus $400M opt-out payment potential.
Takeda leads global commercialization; Protagonist holds option to co-detail in U.S.
Takeda may terminate for convenience after Phase 3 data or 3rd anniversary of effective date.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Protagonist Therapeutics, Inc entered into License and Collaboration Agreement with Takeda Pharmaceuticals USA, Inc. valued at $300 million (effective 2024-01-31).

Action: entry
Agreement: collaboration
Counterparty: Takeda Pharmaceuticals USA, Inc.
Value: $300 million
Effective: 2024-01-31

Exact text from the filing

On January 31, 2024, Protagonist Therapeutics, Inc. (the “ Company ”) entered into a License and Collaboration Agreement (the “ Collaboration Agreement ”) with Takeda Pharmaceuticals USA, Inc. (“ Takeda ”) for the development, manufacture and commercialization of the Company’s rusfertide product candidate

View on SEC.gov

292 material agreements filed in the last 30 days. Browse all material agreements →

Protagonist Therapeutics, Inc filing history →

Source: SEC EDGAR

accession 0001104659-24-008787

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.